All life-saving drugs may come under price cap - (Business Standard via NewsPoints Desk)

  • According to sources India's National Pharmaceutical Pricing Authority is considering a revision of the National List of Essential Medicines (NLEM) to include all live-saving therapies, Business Standard reported.
  • According to a person familiar with the matter, the regulator is also contemplating revising a provision that would allow the agency to monitor the prices of close substitutes and analogues prescribed along with such life-saving medicines.
  • The possible decision could have major implications for large drugmakers such as GlaxoSmithKline, Novartis, Pfizer, Ranbaxy and Sun Pharma, which control large shares of the market.
  • The NPPA's recommendations are expected to go to the Department of Pharmaceuticals in the health ministry next month.
  • "We want to target those segments where volumes are high because consumption is high," stated an NPPA official, adding "however, there is a huge price parity. The expansion of NLEM will try to address this loophole."
  • Specifically, the changes proposed by the NPPA target drugs in the anti-infective, cardiac, gastro-intestinal, respiratory, anti-diabetic, analgesic, neurological and gyneacological markets.

To read more NewsPoints articles, click here.

Reference Articles